KAV13104
Anti-MPXV A35R Human IgA Antibody
Colorimetric
Plasma, Serum
Quantitative
1.56 - 100 ng/mL
0.25 ng/mL
CV<15%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
A Single-Chain Mpox mRNA Vaccine Elicits Protective Immune Response in Mice., PMID:40432124
A Pathogen-Mimicking Monkeypox Virus Nanovaccine Inspired by Assembly of Viral Antigens with β-Glucan and Dendrimer., PMID:40366370
Current status of next-generation vaccines against mpox virus: a scoping review., PMID:40356988
Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice., PMID:40105863
Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775
Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein., PMID:39861905
Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice., PMID:39726255
A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037
Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus., PMID:39423738
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus., PMID:38787725
Levels of antibodies against the monkeypox virus compared by HIV status and historical smallpox vaccinations: a serological study., PMID:38767199
In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722
Screening, Expression and Identification of Nanobody Against Monkeypox Virus A35R., PMID:38076734
Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice., PMID:37800627
Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history., PMID:37784185
A Subunit Vaccine Candidate Composed of Mpox Virus A29L, M1R, A35R, and B6R Elicits Robust Immune Response in Mice., PMID:37766097
mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge., PMID:37739969
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus., PMID:37709783
Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge., PMID:37435062
Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice., PMID:37429529
Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review., PMID:37353117
Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus., PMID:37288876
Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus., PMID:37117161
Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches., PMID:36993967
Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428
Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens., PMID:36687315
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
